MediciNova Inc’s MNOV partners unveiled new data and findings from a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) patients at the Annual Meeting of the Society for Neuro-Oncology.
The primary objectives of this Phase 2 clinical trial were the safety and tolerability of MN-166 (ibudilast) and temozolomide (TMZ) combination treatment and the efficacy of the combination treatment defined as progression-free survival rate at six months using the RANO criteria.
MN-166 (ibudilast) and TMZ combination treatment was safe and well-tolerated, and no unexpected adverse effects were reported.
The presentation also included data from preclinical studies that evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.
- All subjects received TMZ and MN-166 (ibudilast) treatment. Progression-free survival at six months was 44% for new GBM and 31% for recurrent GBM.
- CD3 expression was a good predictor for tumor progression at five months in recurrent glioblastoma subjects treated with MN-166 (ibudilast) and TMZ.
- Median survival was extended to 66 days for the combination therapy of MN-166 (ibudilast) and anti-PD1 inhibitor treatment.
- The addition of MN-166 (ibudilast) to the anti-PD-L1 inhibitor treatment significantly extended survival to a median of 34 days for the combination therapy.
Price Action: MNOV shares are up 14.3% at $2.04 on the last check Monday.
Photo Via Company